From Northeastern University's posting. “We” and “our” refer to the employer.
About the Opportunity
About the Opportunity
Northeastern University Pharmaceutical Industry Fellowships Program is a two-year experiential program designed to advance lifelong learning and the education and training of Pharm.D. graduates. A key element of the program’s success is preparing Fellows to meet evolving workforce needs across various sectors of the pharmaceutical industry.
Fellows have the opportunity to work closely with our innovative biopharmaceutical industry partners, while engaging with Northeastern University faculty in professional and career development, teaching, service, and scholarly activities.
In partnership with Northeastern University, Intellia Therapeutics is offering a two-year Health economics and outcomes research (HEOR) fellowship, based in Cambridge, MA.
About Intellia
Intellia Therapeutics is a Cambridge-based biotechnology company focused on developing clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies to transform lives of people with severe diseases. In fact, Intellia’s co-founder Jennifer Doudna along with Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR.
At Intellia, we are humbled to contribute to what we believe to be medical history. As a leader in this field, our responsibility and commitment to patients is critical in our pursuit of developing novel, potentially curative therapeutics utilizing CRISPR-based technologies.
More specifically, we are employing a modular gene editing platform to create diverse in vivo and ex vivo therapeutics, spanning a range of disease indications. Guided by this full-spectrum approach, we are committed to making CRISPR-based medicines a reality for people living with genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Intellia HEOR Fellowship Program Overview:
Northeastern University Pharmaceutical Industry Fellowships Program is a 2-year experiential program designed to advance lifelong learning and the education and training of PharmD/MPH/PhD graduates. A key element of the program’s success is preparing Fellows to meet evolving workforce needs across various sectors of the pharmaceutical industry.
Fellows have the opportunity to work closely with our innovative biopharmaceutical industry partners, while engaging with Northeastern University faculty in professional and career development, teaching, service, and scholarly activities. In partnership with Northeastern University, Intellia Therapeutics is offering a 2-year Global HEOR and Evidence Strategy fellowship, based in Cambridge, MA.
What Sets the Intellia Fellowship Apart?
During the program, Fellows will work collaboratively and cross-functionally in Intellia’s HEOR and Evidence Strategy team, gaining exposure to our high-energy, fast-paced, and supportive culture. The HEOR and Evidence Strategy team sits within the Market Access and Patient Services team in the Commercial Organization. At Intellia, a technical and scientific expertise background is highly valued.
The Fellowship offers a uniquely structured experience, beginning with a foundational year working with the Director, HEOR and Evidence Strategy supporting the HEOR strategy for Intellia’s novel, gene-editing therapies. This foundational year provides the Fellow with a strong understanding of strategic development of value and evidence generation strategy to support clinical development and commercial brand plans.
In the second year, the Fellow will have an option to participate in 1-3 projects / activities within the broader Market Access and Patient Services team. These optional activities will aim to give the Fellow exposure to key strategic or execution activities that fall within Field HEOR and Market Access Strategy. This will allow the Fellow to gain blended exposure across Intellia’s dynamic business functions and build a versatile skill set for a future in biotech.
Responsibilities
DEVELOP in-depth knowledge of Intellia’s CRISPR gene editing technology, disease and treatment landscape of relevant therapeutic areas—to support strategic evidence generation to support the product value proposition
LEARN to execute global/US HEOR studies which span across the key scientific pillars including; Patient-focused drug development including patient-reported outcomes as key measures in clinical trials
Real-world evidence generation and analysis to identify unmet needs and inform comparative effectiveness, global epidemiology to support regulatory interactions and stakeholder disease education & awareness
Evidence synthesis with literature reviews and indirect/mixed treatment comparisons
Health economic models (cost effectiveness analysis and budget impact analysis), and target patient population tools (US intended use and ex-US target patient population)
Global HEOR activities
In support of US launch – pre-approval information exchange (PIE) tools and post-approval value tools
Strategy and planning related to various country-specific health authority (HTA) interactions and reimbursement dossier development
SUPPORT or LEAD development of HEOR publications for scientific conferences and peer-reviewed journals; ensure the publication plans are up-to-date for HEOR studies
BE an active contributor by helping to executing HEOR tactics including management of external vendors helping with study execution
SUPPORT development of presentations for internal team meetings to drive cross-functional collaboration and discussion to improve the quality of the work
MANAGE HEOR external facing materials development and approval via Veeva PromoMats
Optional project experience with other functions of Market Access and Patient Services in year 2:
Field HEOR: Partner with field teams to translate HEOR evidence into customer-facing value narratives and support scientific exchange with payers/providers, in collaboration with Payer Account Management team.
Market Access Strategy: Contribute to cross-functional market access planning by assessing evidence gaps, evaluating payer landscape insights, and helping shape value propositions across key stakeholder segments.
PARTICIPATE in future fellowship recruitment activities and interviews
Qualifications
Doctor of Pharmacy (PharmD) degree from an ACPE-accredited institution
Eligible for pharmacist licensure in the State of Massachusetts
Elective study or experience related to Epidemiology/Outcomes Research/Health Economics, Statistics/Biostatistics, Real-world Evidence Research, etc. is a plus
Advanced degree (PhD/MS/MPH) in related fields like health economics and outcomes research, epidemiology, or public health is preferred
Excellent oral, written communication, medical writing skills
Strong scientific acumen, ability to simplify complex scientific data, and an interest in gene-editing and CRISPR
Strong time management and leadership abilities
Ability to work independently and take initiative on a variety of projects at both the industry site and Northeastern
Capability for hybrid or in-person work arrangement, with an expectation to be on-site at Intellia approximately 4 times per month, subject to team and project needs
Ability to travel to scientific conferences in the US or internationally per business needs
Additional Information
Applicants should submit the following application materials by the priority deadline of October 31, 2026:
Curriculum vitae (CV), uploaded
Unofficial PharmD transcripts, uploaded
Cover letter, uploaded
Letters of Recommendation
Three formal Letters of Recommendation (LORs) must be submitted directly by the letter writers no later than November 23, 2026 .
Each letter writer must include: The candidate's full name
The fellowship program(s) to which the candidate is applying (e.g., Smith, John – Alnylam, GSK )
Please ask your letter writers to complete and submit the Letter of Recommendation Form along with their recommendation. Click here to access the form and share it with your letter writers.
Recommendations must be submitted directly by the recommender and cannot be submitted by the applicant.
Address cover letter and letters of recommendation to: J. Andrew Orr-Skirvin, PharmD, BCOP
Clinical Professor, Department of Pharmacy & Health Systems Sciences Pharmaceutical Industry Fellowship Program Director
360 Huntington Ave, 140 The Fenway R218 Boston, MA 02115
Northeastern University will not provide H-1B, TN, O-1, E-3, or any other type of employment visa sponsorship for the successful applicant to this position, now or in the future. STEM OPT is not compatible for this position. The successful applicant must be able to maintain valid work authorization in the United States throughout the entire appointment without Northeastern University's sponsorship for a visa.
Position Type
Research
Additional Information
Northeastern University considers factors such as candidate work experience, education and skills when extending an offer.
Northeastern has a comprehensive benefits package for benefit eligible employees. This includes medical, vision, dental, paid time off, tuition assistance, wellness & life, retirement- as well as commuting & transportation. Visit https://hr.northeastern.edu/benefits/ for more information.
All qualified applicants are encouraged to apply and will receive consideration for employment without regard to race, religion, color, national origin, age, sex, sexual orientation, disability status, or any other characteristic protected by applicable law.
Compensation
Compensation Grade/Pay Type:
108S
Expected Hiring Range:
$60,315.00 - $85,192.50
With the pay range(s) shown above, the starting salary will depend on several factors, which may include your education, experience, location, knowledge and expertise, and skills as well as a pay comparison to similarly-situated employees already in the role. Salary ranges are reviewed regularly and are subject to change.
About this listing
LAYIQ is an independent job-discovery service. This listing does not imply a partnership with or endorsement by the employer. Review the original posting for current details and availability.
